FDA Grants Emergency Use of Remdesivir For COVID-19 Patients
Preliminary results suggest it cuts patients' recovery time by four days.
For the first time, the Food and Drug Administration (FDA) has granted its approval to a drug that seems to help COVID-19 patients.
Preliminary results from a government study suggest that remdesivir, an experimental antiviral drug, shortens the time it takes for coronavirus patients to recover by 31 percent, which translates to about four days.
“This is a very, very early stage so you wouldn’t expect to have any sort of full approval at this point,” Cathy Burgess, an attorney specializing in FDA issues, told AP News. “But obviously they want to get this out to patients as quickly as possible.”
The emergency use authorization falls short of full regulatory approval: it acknowledges that the drug hasn’t been tested nearly as rigorously as the FDA would demand under normal circumstances, but given the urgency of the pandemic, it allows doctors to prescribe the drug as they would any other approved medication.
It’s too soon to declare remdesivir a guaranteed fix: in that preliminary trial, the percent of patients who died after taking the drug compared to the percent who died without it was not significantly different, according to CNBC.
All the same, White House health advisor Dr. Anthony Fauci remains optimistic that remdesivir will help the coronavirus effort.
On Wednesday, Fauci told reporters that remdesivir “will be the standard of care.”
As a Futurism reader, we invite you join the Singularity Global Community, our parent company’s forum to discuss futuristic science & technology with like-minded people from all over the world. It’s free to join, sign up now!